Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 18

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 18
---
   | -545 |
| Transactions with subsidiaries that are not issuers or guarantors |   | 6,160 |   |  964 |

Table 14: Obligor group summarised Statement of financial position

| ​                                                                | ​ |         ​ | ​ |         ​ |
| ​                                                                |   | At 30 Jun |   | At 30 Jun |
| ​                                                                | ​ |      2025 | ​ |      2024 |
| ​                                                                | ​ |        $m | ​ |        $m |
| Current assets                                                   |   |        43 |   |        13 |
| Non-current assets                                               |   |       147 |   |         — |
| Current liabilities                                              |   |    -6,506 |   |    -4,795 |
| Non-current liabilities                                          |   |   -24,720 |   |   -27,133 |
| Amounts due from subsidiaries that are not issuers or guarantors |   |    23,554 |   |    20,730 |
| Amounts due to subsidiaries that are not issuers or guarantors   |   |         — |   |         — |

Capital allocation The Group’s capital allocation priorities include: investing in the business and pipeline; maintaining a strong, investment-grade credit rating; potential value-enhancing business development opportunities; and supporting the progressive dividend policy. In approving the declaration of dividends, the Board considers both the liquidity of the company and the level of reserves legally available for distribution. In FY 2025, the Company intends to increase the annual dividend per share declared to $3.20 per share. Dividends are paid to shareholders from AstraZeneca PLC, a Group holding company with no direct operations. The ability of AstraZeneca PLC to make shareholder distributions is dependent on the creation of profits for distribution and the receipt of funds from subsidiary companies. The consolidated Group reserves set out in the Condensed consolidated statement of financial position do not reflect the profit available for distribution to the shareholders of AstraZeneca PLC. In FY 2024, capital expenditure on tangible assets and Software-related intangible assets amounted to $2,218m. In FY 2025 the Group expects to increase expenditure on tangible assets and Software-related intangible assets by approximately 50%, driven by manufacturing expansion projects and investments in systems and technology. Foreign exchange The Company's transactional currency exposures on working capital balances, which typically extend for up to three months, are